Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Status
- COMPLETED
- Phase
- PHASE3
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
B-Cell Hematologic Malignancy Vaccination Registry
- Status
- WITHDRAWN
- Phase
- N/A
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- N/A
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Status
- TERMINATED
- Phase
- PHASE2
Blood Samples to Identify Biomarkers of Busulfan
- Status
- TERMINATED
- Phase
- N/A
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Prolonged Protection From Bone Disease in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE4
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1